Compare Novavax Inc (NVAX) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs VICI Properties Inc — how do they compare? Novavax Inc trades at $7.89 (market cap $1.31B), while VICI Properties Inc trades at $25.96 (market cap $28.61B). The key difference: VICI Properties Inc is far larger — about 21.8× Novavax Inc's market cap, and VICI Properties Inc pays a 6.93% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | VICI | |
|---|---|---|
Market Cap | $1.31B | $28.61B |
Sector | Health | Real Estate |
52-Week High | $11.19 | $33.78 |
52-Week Low | $6.22 | $25.94 |
Enterprise Value | $889.30M | $46.16B |
Dividend Yield | — | 6.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
VICI Properties trades at $25.99, down 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings with an EPS miss but revenue beat, while maintaining strong profitability margins near 67%. Recent news highlights a $1.75 billion notes offering and positive dividend coverage, with analysts largely bullish.
Outlook remains positive given a 6.6% dividend yield, low P/E of 10.07, and consensus price target of $29.83 implying 15% upside. Risks include earnings volatility, high leverage with $843.61M interest expense, and macroeconomic sensitivity affecting real estate valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
